Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Akebia Ther is a biotechnology business based in the US. Akebia Ther shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Akebia Ther employs 426 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $0.41 |
|---|---|
| 52-week range | $0.30 - $3.71 |
| 50-day moving average | $0.39 |
| 200-day moving average | $1.83 |
| Wall St. target price | $1.42 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.60 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.409 from 2022-07-05
| 1 week (2022-06-30) | 15.83% |
|---|---|
| 1 month (2022-06-03) | N/A |
| 3 months (2022-04-07) | -24.47% |
| 6 months (2022-01-07) | -81.49% |
| 1 year (2021-07-07) | -87.90% |
|---|---|
| 2 years (2020-07-07) | -96.86% |
| 3 years (2019-07-05) | 4.38 |
| 5 years (2017-07-07) | 14.21 |
| Revenue TTM | $223 million |
|---|---|
| Gross profit TTM | $-17,922,000 |
| Return on assets TTM | -26.12% |
| Return on equity TTM | -229.73% |
| Profit margin | -123.64% |
| Book value | $0.14 |
| Market capitalisation | $71.4 million |
TTM: trailing 12 months
We're not expecting Akebia Ther to pay a dividend over the next 12 months.
Over the last 12 months, Akebia Ther's shares have ranged in value from as little as $0.3 up to $3.709. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Ther's is 1.5495. This would suggest that Akebia Ther's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.